Overview
- The Wall Street Journal reported that President Trump is considering moving cannabis from Schedule I to Schedule III with a decision expected in the coming weeks.
- Tilray’s shares have surged nearly 10% in a two-day rally, the biggest gain since February 2021, driven by optimism over potential federal policy change.
- On July 28, Tilray reported fiscal fourth-quarter revenue of $224.53 million, missing analyst forecasts; it projected positive adjusted EBITDA for fiscal 2026.
- Tilray is rolling out 10 mg extensions of its HDD9 hemp-derived Delta-9 THC beverage line online and in expanded retail distribution across 10 U.S. states.
- Analysts emphasize that the policy proposal remains unconfirmed, warning that Tilray’s limited U.S. cannabis footprint and history of extreme stock volatility pose significant risks.